TOP TEN perturbations for 1371_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1371_s_at
Selected probe(set): 210272_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1371_s_at (210272_at) across 6672 perturbations tested by GENEVESTIGATOR:

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):6.3655167
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)

Relative Expression (log2-ratio):6.266734
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (confluent)
Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (neuroendocrine carcinoma; primary)

Relative Expression (log2-ratio):5.640622
Number of Samples:2 / 6
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (neuroendocrine carcinoma; primary)
Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):5.4980936
Number of Samples:2 / 3
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (adenosquamous carcinoma; primary)
Primary tumor tissue samples obtained from the lung of patients with adenosquamous carcinoma.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (large cell carcinoma, NOS; primary)

Relative Expression (log2-ratio):4.930249
Number of Samples:2 / 9
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (large cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with large cell carcinoma (NOS).

expO lung cancer study 1 (squamous cell carcinoma, NOS; primary) / expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-4.9102373
Number of Samples:40 / 2
Experimental expO lung cancer study 1 (squamous cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with squamous cell carcinoma (NOS).
Control expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-4.103466
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 3 (area B) / HCC study 3 (area C)

Relative Expression (log2-ratio):-3.8253164
Number of Samples:26 / 24
Experimental HCC study 3 (area B)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the periphery of the tumor (area B). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area C)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 9 (HBV) / normal liver tissue

Relative Expression (log2-ratio):-3.7584486
Number of Samples:10 / 10
Experimental HCC study 9 (HBV)
Liver tissue biopsy sample from patients with Hepatitis B infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-3.754672
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

Organism: Homo sapiens
Gene: 1371_s_at
Selected probe(set): 206755_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1371_s_at (206755_at) across 6672 perturbations tested by GENEVESTIGATOR:

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-6.268093
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

hepatoblastoma study 1 (mixed epithelial and mesenchymal) / normal liver tissue

Relative Expression (log2-ratio):-6.047844
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (mixed epithelial and mesenchymal)
Liver tumor tissue samples from children with hepatoblastoma (mesenchymal type (MEM-HB); mixed epithelial and mesenchymal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (epithelial mixed) / normal liver tissue

Relative Expression (log2-ratio):-5.8439407
Number of Samples:12 / 5
Experimental hepatoblastoma study 1 (epithelial mixed)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (embryonal) / normal liver tissue

Relative Expression (log2-ratio):-5.829359
Number of Samples:7 / 5
Experimental hepatoblastoma study 1 (embryonal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)

Relative Expression (log2-ratio):-5.5807543
Number of Samples:2 / 25
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma.

hepatoblastoma study 1 (NOS) / normal liver tissue

Relative Expression (log2-ratio):-5.465667
Number of Samples:5 / 5
Experimental hepatoblastoma study 1 (NOS)
Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatoblastoma study 1 (crowded fetal) / normal liver tissue

Relative Expression (log2-ratio):-5.0277386
Number of Samples:3 / 5
Experimental hepatoblastoma study 1 (crowded fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); crowded fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

Hep-G2 / HepaRG

Relative Expression (log2-ratio):-4.957409
Number of Samples:9 / 12
Experimental Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

hepatoblastoma study 1 (fetal) / normal liver tissue

Relative Expression (log2-ratio):-4.771188
Number of Samples:4 / 5
Experimental hepatoblastoma study 1 (fetal)
Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); fetal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control normal liver tissue
Normal liver tissue samples.

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):-4.602681
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: